Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 4 to 17 years old, inclusive~* Moderate to severe pain (i.e. FPS-R or vNRS score of 4 or more)~* Requires parenteral opioid analgesic to treat their pain, as decided by treating physician~Exclusion Criteria:~* Allergy or known contraindication to receiving opioids~* Receipt of any opioid or benzodiazepine within preceding 6 hours~* Presence of intranasal obstruction that cannot be cleared readily~* Cannot speak English or Spanish~* Patient unlikely to be able to complete self-report measures of pain or questionnaires~* Known liver or kidney problems~* Currently critically ill~* Chronic pain condition (e.g. sickle cell disease, fibromyalgia)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal hydromorphone (Type: EXPERIMENTAL): Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).